论文部分内容阅读
原发性肝癌(PHC)的早期诊断比较困难,迄今,甲胎蛋白(AFP)仍是诊断PHC唯一最特异性的肿瘤标志物。但由于部分早期及进展期肝细胞癌不分泌AFP,因此约有30％～40％的肝癌病人AFP表现假阴性结果。Deugnier等自1980年以来先后报道PHC病人血清α-L岩藻糖苷酶(AFU)的活性明显升高,提出AFU可作为诊断PHC的新标志物。近几年来,国内也讨论热烈。为此,我们对广东地区223例病人的血清AFU、AFP分别进行检测,以探讨AFU对PHC,尤对AFP阴性的PHC病人的临床诊断价值。现报道如下。 对象及方法 一、观察对象:1992～1993年本院住院部各病区收治的223例病人,其中(1)原发性肝癌50例,男性43例,女性7例,年龄31～73岁,平均年龄50.2岁,均经
Early diagnosis of primary liver cancer (PHC) is more difficult. To date, alpha-fetoprotein (AFP) remains the single most specific tumor marker for the diagnosis of PHC. However, because some early and advanced hepatocellular carcinomas do not secrete AFP, approximately 30% to 40% of liver cancer patients have false negative results. Deugnier et al. have reported that the serum alpha-L fucosidase (AFU) activity in patients with PHC has increased significantly since 1980, suggesting that AFU can be used as a new marker for the diagnosis of PHC. In recent years, domestic discussions have also been enthusiastic. To this end, we detected serum AFU and AFP levels in 223 patients in Guangdong Province to investigate the clinical diagnostic value of AFU in PHC, especially in AFP-negative PHC patients. The report is as follows. Subjects and Methods I. Observed: 223 patients admitted to each ward of the inpatient department of the hospital from 1992 to 1993, including (1) 50 cases of primary liver cancer, 43 cases of male and 7 cases of female, aged 31 to 73 years. The average age is 50.2 years old.